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Abstract
Background: Tropical diseases caused by parasites continue to cause socioeconomic devastation that reverberates
worldwide. There is a growing need for new control measures for many of these diseases due to increasing drug resistance
exhibited by the parasites and problems with drug toxicity. One new approach is to apply host defense peptides (HDP;
formerly called antimicrobial peptides) to disease control, either to treat infected hosts, or to prevent disease transmission
by interfering with parasites in their insect vectors. A potent anti-parasite effector is bovine myeloid antimicrobial peptide-
27 (BMAP-27), a member of the cathelicidin family. Although BMAP-27 is a potent inhibitor of microbial growth, at higher
concentrations it also exhibits cytotoxicity to mammalian cells. We tested the anti-parasite activity of BMAP-18, a truncated
peptide that lacks the hydrophobic C-terminal sequence of the BMAP-27 parent molecule, an alteration that confers
reduced toxicity to mammalian cells.
Methodology/Principal Findings: BMAP-18 showed strong growth inhibitory activity against several species and life cycle
stages of African trypanosomes, fish trypanosomes and Leishmania parasites in vitro. When compared to native BMAP-27,
the truncated BMAP-18 peptide showed reduced cytotoxicity on a wide variety of mammalian and insect cells and on
Sodalis glossindius, a bacterial symbiont of the tsetse vector. The fluorescent stain rhodamine 123 was used in
immunofluorescence microscopy and flow cytometry experiments to show that BMAP-18 at low concentrations rapidly
disrupted mitochondrial potential without obvious alteration of parasite plasma membranes, thus inducing death by
apoptosis. Scanning electron microscopy revealed that higher concentrations of BMAP-18 induced membrane lesions in the
parasites as early as 15 minutes after exposure, thus killing them by necrosis. In addition to direct killing of parasites, BMAP-
18 was shown to inhibit LPS-induced secretion of tumour necrosis factor alpha (TNF-a), a cytokine that is associated with
inflammation and cachexia (wasting) in sleeping sickness patients. As a prelude to in vivo applications, high affinity
antibodies to BMAP-18 were produced in rabbits and used in immuno-mass spectrometry assays to detect the intact
peptide in human blood and plasma.
Conclusions/Significance: BMAP-18, a truncated form of the potent antimicrobial BMAP-27, showed low toxicity to
mammalian cells, insect cells and the tsetse bacterial symbiont Sodalis glossinidius while retaining an ability to kill a variety
of species and life cycle stages of pathogenic kinetoplastid parasites in vitro. BMAP-18 also inhibited secretion of TNF-a, an
inflammatory cytokine that plays a role in the cachexia associated with African sleeping sickness. These findings support the
idea that BMAP-18 should be explored as a candidate for therapy of economically important trypanosome-infected hosts,
such as cattle, fish and humans, and for paratransgenic expression in Sodalis glossinidius, a bacterial symbiont in the tsetse
vector, as a strategy for interference with trypanosome transmission.
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Introduction
Trypanosomatid protozoan parasites cause a variety of diseases
that affect the livelihood of people in vast areas of the world.
Control of such diseases depends, to a large extent, on a small set
of prophylactic and therapeutic anti-parasite drugs [1]. However,
as with many microbes, inappropriate use of these agents has led
to an alarming increase in parasite resistance, for example with
African trypanosomes and Leishmania [2,3]. This has created a
need for novel compounds to prevent and cure diseases caused by
these predominantly tropical parasites. An ideal anti-parasite
agent would have a broad spectrum of activity, would be largely
unaffected by mutations in the target microbe and be non-toxic in
vivo. Effectors with such potential are the host defense peptides
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(HDP), ancient and highly successful molecules that remain
functional over long periods of evolution, suggesting that microbial
resistance to them is not inevitable.
HDP are widely distributed elements of immunity that show a
broad spectrum of activity against a variety of bacteria, fungi,
parasites, enveloped viruses and transformed cells [4]. HDP are
evolutionarily conserved peptides that have received much
attention from the medical research community for their versatility
and potential as alternatives to existing antimicrobials, many of
which have become less effective due to increasing resistance in the
target populations [2,3]. In some cases, HDP have advantages
over traditional drugs and antibiotics, including having a much
wider spectrum of activity and an apparent robustness against
resistance. Most importantly, HDP naturally occupy positions in
immunity as innate immune mediators [4] and thus may show
pleiotropic activity in controlling infections.
HDP are expressed by a variety of cells as holoproteins that are
cleaved proteolytically to release the active peptides. An impressive
repertoire of more than 1000 HDP have been reported in the
antimicrobial peptide database [5,6]. Many of these molecules
target pathogens directly by disturbing the pathogen’s membrane
potential or by interfering with cell functioning internally, thus
causing cell death by either necrosis or apoptosis. Perhaps as
important, because many HDP selectively modulate host innate
immune responses, they may exhibit multi-pronged effector
functions. HDP, many of which were first detected by their direct
antimicrobial properties, show variable chemotactic influences on
a variety of immune cells including monocytes, neutrophils,
eosinophils and T cells [7,8]. In addition, HDP can be potent and
selective anti-inflammatory agents, that suppress the production of
pro-inflammatory cytokines in response to lipopolysaccharide, and
can enhance protective immunity and promote the transition to
adaptive immunity [4]. The local antimicrobial protection
conferred by peptides released at the site of challenge is enhanced
by the complex interaction of these peptides with innate and
adaptive elements of the immune system [8].
The cathelicidins are a family of HDP, some of which are
produced and stored in the neutrophils of many mammalian
species [9]. All members of the cathelicidin family contain a C-
terminal cationic domain and an N-terminal cathelin portion that
must be cleaved to release the active C-terminal peptide. Bovine
myeloid antimicrobial peptide-27 (BMAP-27) [10] is one such
active peptide (not to be confused with the very different BMAP-
28 molecule [10]), with a predicted cationic N-terminal amphi-
pathic helix and a hydrophobic C-terminal tail. BMAP-27 has
been shown to have potent antimicrobial activity on bacteria [10],
fungi [11], chlamydia [12] viruses [13] and parasites [14,15].
However, BMAP-27 showed some cytotoxic activity on human
cells (erythrocytes and neutrophils [10]) and thus was subsequently
modified by cleaving off the C-terminal hydrophobic tail to reveal
a potent antimicrobial peptide, BMAP-27 [1–18] (hereafter called
BMAP-18), which demonstrated reduced toxicity to human cells.
Previous work in our lab showed that African trypanosomes
were effectively killed in vitro with low concentrations of the
BMAP-27 peptide, although cytotoxicity to mammalian cells was
also observed [15]. The strong anti-parasite activity observed with
BMAP-27 inspired us to further investigate BMAP-27 and its
truncated form, BMAP-18, for their effects on a variety of species
and life cycle stages of kinetoplastid parasites and on a range of
mammalian and insect cell lines. Our goal was to qualify BMAP-
18 as an effective in vitro anti-parasite effector and to lay the
groundwork for further investigations into using BMAP-18 as a
novel therapeutic in vivo. Our results support the idea that BMAP-
18 is a strong candidate for possible use as a therapeutic in animals
for treating trypanosome infections or in the tsetse vector as a
parasite transmission blocking agent.
Materials and Methods
Trypanosomes
Bloodstream forms (BSF) of T. b. brucei 427.01 [16] were
obtained from Dr. Sam Black (Amherst, MA) and adapted to
growth in vitro. In brief, upon thaw, BSF trypanosomes (a dilution
series from 106–103/mL) were grown at 37uC in flat-bottomed 24-
well tissue culture plates (Falcon 3047, Becton-Dickinson, Lincoln
Park, NJ) in modified Baltz’s medium supplemented with 10%
heat-inactivated fetal bovine serum (FBS) [17]. Trypanosomes
were examined daily in each well and only those wells showing
healthy organisms in log-phase of growth were chosen for further
subculture and use in minimal inhibitory concentration (MIC)
assays (see below). Procyclic culture forms (PCF) of T. b. brucei
427.01, T. b. gambiense U2 [18], T. b. rhodesiense ViTat 1.1 [19], and
T. congolense IL3000 [20] were derived from their corresponding
BSF by transformation at 27uC [21]. Tsetse transmissible T. b.
brucei TSW 196 PCF [22] were obtained from the Liverpool
School of Tropical Medicine. All PCF were cultured in MEM/
10% FBS as described [20,23]. The fish pathogen T. danilewskyi
strain TrCa was obtained from Mike Belosevic and Debbie Plouffe
(University of Alberta) and were grown in vitro as described [24].
Leishmania
Promastigotes of Leishmania donovani LD3 [25] were obtained
from Dr. Sam Turco (Lexington, KY). Leishmania promastigotes
were adapted to a modified minimal essential medium (MEM)
containing 10% FBS [20,23] and maintained in culture in vitro at
27uC.
Mammalian cell lines
B lymphocyte hybridomas 2A11 (anti-hypoderma C) and 10B1
(anti-trypanosome tubulin) were of murine origin (BALB/c) and
secrete IgG1 mAbs (Pearson lab, unpublished). EL4 thymoma cells
were also of murine origin [26]. NIH 3T3 cells were derived from
Author Summary
Protozoan parasites cause serious diseases in large areas of
the tropics. Control of these diseases depends to a great
extent on the use of therapeutic drugs, many of which are
highly toxic. In addition, parasite resistance to several of
the front-line drugs is increasing. Host defense peptides
(HDP; formerly called antimicrobial peptides) have recently
received attention as potential anti-parasite effector
molecules. We earlier reported that one such peptide,
bovine myeloid antimicrobial peptide (BMAP-27), is a
potent inhibitor of the growth of trypanosomes and
Leishmania in vitro. Here we report our studies on BMAP-
18, a truncated form of BMAP-27, which showed reduced
toxicity to mammalian and insect cells and yet retained its
direct toxicity to parasites in vitro. BMAP-18 also strongly
inhibited LPS-induced release of tumour-necrosis factor
alpha (TNF-a) from human leukocytes, and thus has
immunomodulatory activity. These findings suggest that
BMAP-18 has potential as a therapeutic agent for
treatment of infected animals or as an inhibitor of parasite
transmission by their insect vectors. In anticipation of
using BMAP-18 in vivo, we have also developed high
affinity antibodies to BMAP-18 and have shown that these
can be used, in conjunction with mass spectrometry, to
detect the peptide in whole blood or plasma.
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an embryonic fibroblast cell line originally isolated from Swiss
mice [27]. NR8383 alveolar cells were derived from a Sprague-
Dawley rat lung [28]. HeLa cells were originally established from a
cervical carcinoma of human origin [29]. All mammalian cell lines
were grown in Dulbecco’s Modified Eagles Medium (Gibco BRL
cat no. 23700-057) supplemented with 10% FBS, L-glutamine,
sodium pyruvate, 561025 M 2-mercaptoethanol and penicillin/
streptomycin.
Insect cell lines
CF70 cells were derived from ovarian cultures of the eastern
spruce budworm Choristoneura fumiferana [30]. Sf9 cells were derived
from pupal ovarian tissue of the fall armyworm Spodoptera frugipera
[31]. FPMI-NL-18 cells were established from the embryonic
tissues of the red-headed pine sawfly, Neodiprion lecontei [32]. Stocks
of all insect cells were obtained from Beatrixe Whittome [Dept. of
Biology, UVic]. Insect cell lines were grown in Grace’s insect
medium [33] containing 15% FBS and 0.25% (w/v) bacto tryptose
broth (Difco; Becton Dickinson, Oakville, ON).
Sodalis glossinidius
Sodalis glossinidius, a secondary symbiont of tsetse flies (Glossina)
[34], were isolated at the University of Alberta according to the
protocol of Welburn and Maudlin [35], modified by changing the
method used to maintain asepsis prior to initial culture [36]. In
brief, S. glossinidius from tsetse hemolymph were initially grown on
monolayers of Aedes albopictus cells and after 20 days in culture were
adapted to axenic growth in serum-free medium [36]. The
relatively slow growing bacteria were maintained by passaging
every 5 days. Clones were isolated by spreading 2 ml of culture
aseptically onto Mitsuhashi and Maramorosch (MMI) agar plates
(1% (w/v) agar (Difco, Detroit, MI) followed by a 15 min
incubation at room temperature to allow the culture to absorb
into the agar. The plates were then placed in an unvented BBL
GasPakTM anaerobic jar with a BBL CampyPak PlusTM system
(Becton Dickinson, Sparks, MD) to generate microaerophilic
conditions. Incubation at 27uC for 7 days resulted in small, white,
papillated colonies. Culture purity was monitored by Coomassie
Brilliant Blue staining of SDS-PAGE-separated proteins that yield
a unique banding pattern [36] and by polymerase chain reaction
using S. glossinidius-specific primer sets [34].
BMAP-27 and BMAP-18 host defense peptides
The cathelicidins BMAP-27 and BMAP-27 [1–18] (BMAP-18)
were synthesized by Fmoc (N-(9-fluorenyl) methoxycarbonyl)
chemistry at the University of British Columbia’s Nucleic Acid/
Protein Services Facility. A comparison of the BMAP-27 and
BMAP-18 sequences is shown in Figure 1. BMAP-18 was also
synthesized with a C-terminal cysteine for coupling of the peptide
to the protein carrier keyhole limpet hemocyanin (KLH) for
polyclonal antibody production and for affinity purification of the
resultant antibodies (see below). The peptides were analysed for
purity by high-performance liquid chromatography and for
identity (and purity) by matrix-assisted laser desorption ionization
time of flight (MALDI-TOF) mass spectrometry. All peptides were
of greater than 80% purity. Lyophilized peptides were dissolved in
sterile distilled water to a final concentration of 2.0 mg/mL and
dilutions were prepared for inhibition assays, for enzyme-linked
immunosorbent assays (ELISA), for affinity purification of
antibodies and for immuno-mass spectrometry assays as described
below.
Inhibition of eukaryotic and prokaryotic cells by BMAP-27
and BMAP-18
Minimal Inhibitory Concentration (MIC) assays were per-
formed on trypanosomes, Leishmania, mammalian cell lines, insect
cell lines and the bacterium Sodalis glossinidius using the
chromogenic/fluorogenic substrate alamarBlue [37] as previously
described [15] with minor changes. In brief, healthy, log phase,
BSF and PCF trypanosomes, Leishmania promastigotes, mamma-
lian cells and insect cells were adjusted to 2.06104 cells/mL in
fresh medium and 100 mL (2.06103 cell/well) were dispensed into
wells of round-bottom 96-well polypropylene microtitre plates
(COSTAR/ Corning Inc, Corning, New York: Cat. No. 3790)
containing serial dilutions (10 mL in 0.2% FBS) of the BMAP-27
and BMAP-18 peptides. One exception was that T. danilewskyi BSF
were adjusted to 56104 cells/mL and 100 mL (56103) were seeded
per well. After 66 hours of incubation at 37uC (for BSF and
mammalian cells) or 27uC (for PCF, T. danilewskyi, Leishmania
promastigotes, insect cells and S. glossinidius), 10 mL of alamarBlue
(BioSource International, Inc., Camarillo, CA) were added to each
well and the plates were incubated for another 6 h (final
incubation of 72 h). Seventy mL of cell free supernatant from
each well were then transferred into 96-well flat-bottomed black/
white microplates (Greiner Bio-One, CellStar, Cat no. 655079,
MJS Biolynx, Brockville ON) for fluorescence measurement.
Fluorescence was measured using a Cytofluor 2300 microplate
reader (Millipore, Bedford, MA) set to an excitation wavelength of
540 nm and an emission wavelength of 590 nm. The alamarBlue
assay measures cell viability and proliferation based on detection
of metabolic activity [38]. The alamarBlue colorimeteric/fluoro-
metric growth indicator incorporates an oxidation-reduction
indicator that changes colour in response to chemical reduction
by metabolically active cells. Growth related reduction causes the
indicator to change from oxidized (blue, non-fluorescent) to
reduced (red, fluorescent).
S. glossinidius were cultured in Mitsuhashi and Maramorosch
broth (Sigma-Aldrich Canada, Oakville, ON) for 3 days at 27uC in
an atmosphere of 5% CO2 in air [36]. Cultures were diluted in
fresh medium to 56105 bacteria per mL using the following
Figure 1. The Amino Acid Sequences of BMAP-27 and BMAP-18 peptides. The entire prepro sequence of the Bovine Myeloid Antimicrobial
Peptide-27 (BMAP-27) precursor is shown. The Antimicrobial Peptide Database [6] ID number for BMAP-27 is: AP00366. The N-terminal cathelin
domain is proteolytically cleaved to release the C-terminal antimicrobial peptide BMAP-27, shown in red type. The truncated BMAP-18 sequence
(designated with the asterisk*, with the C-terminal hydrophobic 9-mer removed) is shown in blue type below the BMAP-27 sequence.
doi:10.1371/journal.pntd.0000373.g001
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conversion: OD600 of 0.8 = 1610
9 bacteria/ml. Diluted bacterial
suspensions (100 mL) and peptides (10 mL of each dilution) were
loaded into the wells of round-bottom microtitre plates as
described above. Because of the slower growth rate of S. glossidinius,
alamarBlue was added after 72 hours and 6 hours later, the plate
contents were transferred into flat-bottomed black/white micro-
plates for fluorescence determination as described above.
Scanning electron microscopy
Suspensions of parasites (106 in 500 mL PBS containing 25 mg
BMAP-18) were incubated for 15 min at 37uC (BSF trypano-
somes) or 27uC (PCF trypanosomes or Leishmania promastigotes).
The treated cell suspensions were mixed with an equal volume of
fixative containing 3% formaldehyde and 3% glutaraldehyde in
0.1 M sodium cacodylate buffer and placed in a fridge at 4uC for
overnight fixation. The next day, after warming to room
temperature, the fixed parasites were centrifuged in 1.5 ml
Eppendorf microcentrifuge tubes, the supernatant decanted and
replaced with new fixative. This procedure was repeated, to ensure
the complete removal of serum from the parasites thus allowing
them to bind to polylysine coated slides. An aliquot of each sample
was placed onto separate 0.1% poly-l-lysine (Sigma Chemical
Company, St. Louis, MO) treated 10 mm circular glass cover slips
and these were incubated in a humid chamber for 1 hour. After
washing in Karnovsky’s cacodylate buffer, the samples were
dehydrated in a graded ethanol series and critical point dried using
liquid carbon dioxide. The cover slips were glued with silver paste
onto labeled aluminum scanning electron microscopy stubs and
sputter coated with gold in an Edwards S150B Sputter Coater.
Digital images were collected using a Hitachi S-3500N Scanning
Electron Microscope operating at 10 kV at 50006magnification.
Measurement of mitochondrial activity using fluorescent
rhodamine 123
Trypanosomal mitochondrial activity was measured using the
fluorescent, cell-permeant, cationic fluorescent dye rhodamine 123
(R-302; Molecular Probes, Eugene, OR) that is sequestered by
active mitochondria [39]. Wild type T. b. brucei 427.01 PCF
(16107/mL) were incubated at 27uC for 10 minutes with 250 nM
(final concentration) rhodamine 123 (Cat. No. R8004, Sigma St
Louis, MO) and then BMAP-18 peptide (5 mL of 1.0 mg/
mL=5 mg) was added. At intervals, trypanosomes were analyzed
by immunofluorescence microscopy and by flow cytometry.
Trypanosomes were first examined by light- and fluorescence
microscopy (for observation of rhodamine 123 fluorescence) using
a Zeiss Standard binocular microscope fitted with an epifluores-
cence attachment and a Zeiss NeoFluor 63/1.25 oil immersion
objective. Digital photographs were taken with a Nikon CoolPix
2700 camera at high resolution. The images were stored and
manipulated in TIFF format using PhotoshopTM 5.5 graphic
software (Adobe Systems Inc., San Jose, CA). The same
populations of trypanosomes were analyzed for forward scatter
(size), side scatter (granularity) and fluorescence (rhodamine 123)
using a FACSCalibur flow cytometer (Becton-Dickinson, San Jose,
CA). For each sample, a minimum of 10,000 events were
analyzed.
Immunomodulatory effects of BMAP-27 and BMAP-18
Human venous blood (100 mL) was collected from healthy
volunteers in Vacutainer collection tubes containing heparin (Cat
No. 362753, BD, Franklin Lakes, NJ) according to the University
of British Columbia Clinical Research Ethics Board guidelines and
approval. The blood was mixed at a 1:1 ratio with RPMI 1640
medium (supplemented with 10% (v/v) FBS, 2 mM L-glutamine,
and 1 mM sodium pyruvate) and the peripheral blood mononu-
clear cells (PBMC) were separated by centrifugation in Ficoll-
PaqueTM PLUS (Cat No. 17-1440-02, GE Healthcare). PBMCs
were isolated from the buffy coat, washed twice in sterile PBS and
the numbers of live cells were determined by trypan blue
exclusion. PBMCs (0.1 mL at 16106 cells/mL) were seeded into
96-well tissue culture dishes (Sarstedt), incubated at 37uC in 5%
CO2 in air and rested for 2 h before experimental treatment.
To measure cytokine stimulation, PBMCs were treated for 24 h
with doubling dilutions (100 mg/mL-1.56 mg/mL) of BMAP-18
and BMAP-27. Monocyte chemotactic protein-1 (MCP-1), the
chemotactic cytokine Gro-alpha (Gro-/), and tumour necrosis
factor alpha (TNF-a) were measured in culture supernatants using
ELISAs (see below). To test for anti-endotoxin activity, PBMCs
were pretreated with 5 mg/mL BMAP-18 or BMAP-27 for
30 minutes prior to the addition of 10 ng/mL of purified
Pseudomonas aeruginosa LPS for 4 hours. Pseudomonas aeruginosa LPS
was purified as described previously [40]. After 4 hours, secreted
TNF-/ was measured by ELISA (see below).
All tissue culture supernatants were centrifuged at 10006 g for
10 min to remove cells, aliquoted and then stored at 220uC
before assaying for cytokines by ELISA, according to the
manufacturer’s instructions (MCP-1 and TNF-a, eBioscience
Inc., San Diego, CA; Gro-a, R&D Systems, Minneapolis, MN).
BMAP-18-specific antibodies
Immunization of rabbits was performed to obtain high affinity
polyclonal antibodies specific for BMAP-18. Two female New
Zealand White rabbits were bled to obtain preimmunization sera
and after one day of rest were immunized with BMAP-18-KLH
conjugate (subcutaneous injections of 0.25 mg in complete
Freund’s adjuvant). Four subsequent subcutaneous injections
containing 0.25 mg of peptide-KLH conjugate in incomplete
Freund’s adjuvant were given using standard procedures. At
intervals, to determine if an adequate immune response had been
achieved, test bleed sera were prepared and titrated using the
unconjugated, ‘‘immunizing peptides’’ in an ELISA where the
peptide antigens are dried onto assay plates (see ‘‘peptide ELISA’’,
below). Once adequate antibody responses were achieved, antisera
were prepared from several bleeds from each rabbit. Affinity
purified anti-BMAP antibodies were obtained by elution from an
immunoadsorbent made by covalent coupling of BMAP-18
peptide through an added C-terminal cysteine to SulfoLinkH
Coupling Gel (Cat No. 20401; Pierce, Rockford IL). The
antibodies were used in ELISA and in an immuno-mass
spectrometry assay (see below) to detect BMAP-18 peptide in
human blood or in plasma.
Peptide ELISA
A modified ELISA was used to measure specific anti-BMAP-18
antibody titres and to detect BMAP-18 in human serum samples.
First, a standard ELISA method [41] was modified to use anti-
rabbit alkaline phosphatase second antibodies and free peptide
antigens (i.e. not coupled to protein carriers) to coat the
polystyrene microtitre ELISA plates. In this specialized ‘‘peptide
ELISA’’, peptide was dissolved in distilled water to 5.0 mg/mL
and 100 mL (0.5 mg/well) of this solution were dried onto each
well by overnight incubation at 37uC in a dry incubator. Dilutions
of the rabbit antisera were then used as a source of primary
antibodies to determine the titres. To determine if BMAP-18 could
be detected in complex protein mixtures, 0.5 mg amounts of
BMAP-18 were spiked into 100 mL of serially diluted human
serum and dried onto ELISA plates overnight, prior to adding a
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1/400 dilution (predetermined from the titration data) of first
antibody, followed by second antibody and substrate.
Detection of BMAP-18 by immuno-mass spectrometry
An immunoenrichment technique coupled with peptide detec-
tion by mass spectrometry was also used to detect BMAP-18 in
human blood and plasma. We used immuno-matrix assisted laser
desorption ionization (iMALDI) time of flight mass spectrometry
to detect BMAP-18 by its characteristic mass. To do this, 1 mg of
BMAP-18 was spiked into 50 mL aliquots of freshly prepared
undiluted human blood, plasma or serum, 2 mg of affinity purified
rabbit antibody were added to each sample and the mixtures were
incubated (with shaking) for 18 hours at 4uC to allow antibody-
peptide binding. Negative controls consisted of all three samples
without added peptide. Another negative control consisted of
50 mL of PBS containing 2 mg of a ‘‘wrong’’ affinity purified
antibody and 1 mg of BMAP-18 peptide. A positive control
consisted of 50 mL of PBS containing 2 mg of anti-BMAP-18
affinity purified antibody with 1 mg BMAP-18 peptide. After
18 hours of incubation, 10 mL of a suspension of washed
Dynabeads (M-280; sheep anti-rabbit IgG; cat no. 112.03D) were
added to all of the experimental samples, the mixtures were
incubated for 2 hours at room temperature and the beads from
each were washed three times with PBS before eluting the peptides
with 25 mL of 5% acetic acid. The 25 mL samples were Zip-
Tipped (C18; P10 tip size; Cat No. ZTC18S960; Millipore
Corporation, Billerica, MA) to concentrate the eluted peptides
and to remove salts and then the peptides were eluted in 1 mL of
50% acetonitrile/0.1% trifluoroacetic acid. MALDI-TOF analysis
was performed by spotting the eluted peptides (all of the 1 mL)
onto the wells of a Voyager, 100 position, stainless steel MALDI
plate (Applied Biosystems, Foster City, CA). After drying, the
peptide spots were covered with 1 mL of matrix (0.5% alpha-
cyano-4-hyrdoxycinnamic acid/0.18% ammonium citrate/70%
acetonitrile/0.1% trifluoroacetic acid). An Applied Biosystems
Voyager DE-STR mass spectrometer (Applied Biosystems, Foster
City, CA) running in delayed extraction, reflectron mode was used
to acquire MALDI-TOF data.
Results
The effect of BMAP-27 and BMAP-18 on kinetoplastid
parasites and the bacterial symbiont of tsetse, Sodalis
glossinidius
To compare the growth inhibitory activity of the full-length
bovine cathelicidin BMAP-27 with its truncated form, BMAP-18,
both BSF and PCF of T. b. brucei parasites were cultured in the
presence of varying concentrations of the peptides. After
incubation for 66–72 hours, the metabolic activity of the
organisms was determined using alamarBlue substrate. The results
are shown in Figure 2A. Both life cycle stages of the trypanosomes
were inhibited by BMAP-27 at extremely low concentrations (50%
inhibition at ,2 mg/mL for BSF, solid black line; and ,10 mg/
mL for PCF, solid gray line). The truncated BMAP-18 exhibited
similar effects, with strong inhibition of both BSF and PCF
trypanosomes observed at low doses of the peptide (50% inhibition
at 8 and 12 mg/mL respectively). In comparison, a bacterial
symbiont of tsetse, Sodalis glossinidius was not killed as effectively
(green lines), especially with BMAP-18 (dashed green line) that
required at least a ten-fold higher concentration (50% inhibition at
100 mg/mL) of peptide to effect similar levels of growth inhibition.
To test the parasite specificity of BMAP-18, several species of
kinetoplastid parasites were tested in inhibition assays. The results
are shown in Figure 2B. T. b. brucei, T. b. gambiense and T. b.
rhodesiense PCF, members of the subgenus genus trypanozoon and
species that are pathogens of domestic animals and humans,
showed strong growth inhibition by low doses (50% inhibition at
,10 mg/mL to a maximum of 25 mg/mL) of BMAP-18. T.
congolense, a member of the subgenus Nannomonas, was also
strongly inhibited by BMAP-18. Promastigote forms of Leishmania
donovani parasites and the non-African trypanosome, T. danilewskyi,
a pathogen of fish, were also highly sensitive to killing by BMAP-
18.
The effect of BMAP-27 and BMAP-18 on mammalian and
insect cell lines
Both mammalian cells and insect cells were tested in the
alamarBlue assay with both forms of BMAP. The results are
shown in Figure 3. All of the mammalian cell lines tested were
less sensitive to BMAP-18 than to BMAP-27 (Panel A). Even the
rapidly growing hybridoma cell line was less sensitive than T. b.
brucei (shown on the left side of each of the panels) used as a
comparative positive control. Similarly, BMAP-18 showed
reduced cytotoxicity (approximately 2–8 fold) on all insect cell
lines (Panel B) when compared with the parental BMAP-27
peptide.
Physical effects of BMAP-18 on various kinetoplastid
populations
T. b. brucei 427.01 PCF, T. b. rhodesiense BSF and L. donovani
populations were treated with high doses (50 mg/mL) of BMAP-
18, fixed and examined by scanning electron microscopy at 50006
magnification (Figure 4). All three species of parasites showed
membrane damage after treatment with BMAP-18 (Panels 2, 4, 6)
whereas membranes of untreated parasites remained intact (Panels
1, 3, 5). Three individual T. b. brucei 427.01 PCF trypanosomes
were photographed in the same microscopic frame in various
stages of BMAP-18-based destruction after 15 min incubation
(Panel 7). After 30 min incubation, no parasites had survived (not
shown).
Effects of BMAP-18 on rhodamine 123 retention in
trypanosomes
Rhodamine123 is a cell permeant fluorescent dye that
accumulates in mitochondria, which run the entire length of the
trypanosome body. It is thought that an attraction of cationic
rhodamine 123 molecules by the relatively high negative electric
potential across the mitochondrial membrane may be the basis for
the selective staining of mitochondria by rhodamine 123 in living
cells. The dye at low concentrations exhibits no cytotoxicity [40].
It is used, among other things, to indicate mitochondrial
membrane disruption. After incubating T. b. brucei 427.01 PCF
with rhodamine123 and subsequently treating the same popula-
tions with low-doses (5 mg/mL) of BMAP-18, we assessed the dye
retention of the cells by fluorescence microscopy (Figure 5).
Trypanosomes were first treated with rhodamine 123 and
photographed. These control (untreated) parasites showed bright
red fluorescence distributed along the mitochondria (Panel A1).
Rhodamine 123 labeled trypanosomes were then treated with
BMAP-18 for 10 min and photographed again. This time no
fluorescence was observed (Panel A2), indicating that the
mitochondrial potential was disrupted, releasing the dye. These
results were confirmed by flow cytometry over a 0–30 minute time
course (Figure 5B). The plot clearly shows decreasing rhodamine
123 fluorescence as the incubation period of BMAP-18 with the
trypanosomes was extended. A dot-plot comparison shows the
effects of BMAP-18 treatment on mitochondrial fluorescence vs.
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Figure 2. Inhibition of parasite growth by BMAP-27 and BMAP-18 peptides. MIC assays were performed on trypanosomes and Leishmania
using alamarBlue as described in the Materials and Methods. Panel A: Comparison of full length and truncated host defense peptides. T. b. brucei
427.01 BSF (black lines), PCF (gray lines) and Sodalis glossinidius (green lines) were tested for sensitivity to BMAP-27 (solid lines) and BMAP-18 (dashed
lines). Percent inhibition is shown as a function of peptide concentration. Panel B: Growth inhibition of a variety of kinetoplastid parasites by BMAP-
18. T. b. brucei 427.01 PCF (black line), T. b. brucei TSW196 PCF (magenta line), T. b. rhodesiense ViTat 1.1 PCF (solid green line), T. b. gambiense U2 PCF
(red line), T. congolense IL3000 PCF (orange line), T. danilewskyi TrCa (dashed green line), L. donovani LD3 (dashed blue line). The results shown are
representative of more than 10 individual experiments (Panel A) or 4 individual experiments (Panel B) performed over a one year period.
doi:10.1371/journal.pntd.0000373.g002
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side scatter (granularity) over time (Figure 5C). The diluent control
(untreated trypanosomes after 30 min; far right panel) showed that
approximately 83% of the parasites were alive and healthy as they
had strong rhodamine 123-stained mitochondria and low
granularity. After incubation with BMAP-18, the parasites
remained intact and appeared to have a normal plasma
membrane but showed decreasing rhodamine fluorescence and
increasing granularity as the cells rounded up and underwent an
apoptosis-like death. In other experiments (not shown) the vital
dye fluorescein diacetate was retained by the parasites incubated
with low levels (5 mg/mL) of BMAP-18, indicating that the
integrity of the plasma membrane was maintained.
Figure 3. Comparative effects of BMAP-27 and BMAP-18 on growth of mammalian and insect cell lines. Inhibition assays using
alamarBlue (as described in Materials and Methods) were performed on a variety of cell lines grown in vitro. A range of concentrations of peptides
was tested against all cell lines. The concentrations of peptides required for 50% inhibition (MIC50) are shown. A representative parasite, T. b. brucei
427.01 PCF, treated under the same conditions, is included to indicate the marked difference in peptide concentrations required for inhibition of
parasite and mammalian cell lines. Panel A: Mammalian cell lines. Panel B: Insect cell lines. Black bars: BMAP-27; Gray bars: BMAP-18. The results
shown are representative of three individual experiments performed over a one year period.
doi:10.1371/journal.pntd.0000373.g003
Figure 4. Scanning electron micrographs of trypanosomes and Leishmania before and after treatment with BMAP-18. Parasites in log-
phase of growth were treated with BMAP-18 peptide (high concentration; 50 mg/mL) in vitro for 15 minutes before fixing and processing for
microscopy. T. b. brucei 427.01 PCF, T. b. rhodesiense BSF and L. donovani. Panel 1: untreated T. b. rhodesiense BSF, Panel 2: BMAP-18-treated T. b.
rhodesiense BSF. Panel 3: Untreated T. b. brucei 427.01 PCF, Panel 4: BMAP-18 treated T. b. brucei 427.01 PCF, Panel 5: untreated L. donovani LD3
promastigotes, Panel 6: BMAP-18 treated L. donovani LD3 promastigotes, Panel 7: BMAP-18 treated T. b. brucei 427.01 BSF trypanosomes seen in
the same microscopic field. All parasites are shown at 50006magnification (5 mm bar = 1 micron).
doi:10.1371/journal.pntd.0000373.g004
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Immunomodulatory activity of BMAP-27 and BMAP-18
Both BMAP-27 and BMAP-18 were tested for their ability to
induce release of the cytokines MCP-1, Gro-a and TNF-a from
human PBMC. In four separate experiments, BMAP-27, at a
range of concentrations, stimulated release of MCP-1 and Gro-a
cytokines, whereas BMAP-18 at the same range of concentrations
did not. Neither BMAP-27 nor BMAP-18 directly stimulated the
release of TNF-a from PBMC (data not shown). However, in three
separate experiments, both BMAP-27 and BMAP-18, at physio-
logically relevant concentrations, strongly inhibited LPS-induced
TNF-a secretion from PBMC (Figure 6).
Immunodetection of BMAP-18 peptide in blood and
plasma
A modified ‘‘peptide ELISA’’ (see Methods) was used to
measure the titres of rabbit anti-BMAP-18 antibodies without
Figure 5. Analysis of trypanosomal mitochondrial activity by fluorescence microscopy and flow cytometry before and after
treatment with BMAP-18. T. b. brucei 427.01 PCF were incubated with rhodamine123 as described in the Materials and Methods, examined by
fluorescence microscopy and digitally photographed (Panel A1). The rhodamine 123 labeled trypanosomes were then treated with a low dose of
BMAP-18 (5 mg/mL) and photographed again (Panel A2). Rhodamine fluorescence (FL-2) was also monitored by flow cytometry, before and after
varying intervals of BMAP-18 treatment (Panel B). The different colours indicate different incubation times with the BMAP-18 peptide. Red: diluent
control, 30 min; Yellow: BMAP-18 treated, 5 min; Green: BMAP-18 treated, 10 min; Light blue: BMAP-18 treated, 20 min; Dark blue: BMAP-18 treated,
30 min. The plot clearly shows decreasing rhodamine 123 fluorescence as the incubation period of BMAP-18 with the trypanosomes was extended
from 0–30 minutes. A dot-plot comparison of this experiment (Panel C) showed the effects of BMAP-18 treatment on fluorescence intensity vs side
scatter (cell granularity) over time. The numbers in the upper right quadrants of the dot-plots indicate the percentage of healthy cells with strong
mitochondrial rhodamine fluorescence. In Panel B, the horizontal (X) axis indicates arbitrary fluorescence units and the vertical (Y) axis indicates the
number of cells (events). In Panel C, the Y axis is SSC (side scatter).
doi:10.1371/journal.pntd.0000373.g005
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interference from the linker moieties used to couple peptides to the
KLH carrier used for immunization. Titres of rabbit antisera in
excess of 1:6400 were obtained. To test the utility of these antisera
for detection of BMAP-18 in complex antigenic mixtures, a
dilution series of human serum was made and 0.5 mg BMAP-18
peptide was spiked into 100 mL of each dilution for antigen
coating of ELISA plates. The rabbit antibodies detected the
BMAP-18 peptide even in undiluted human serum (data not
shown) thus affinity-purifed anti-BMAP-18 antibodies were
prepared for use in a novel immuno-mass spectrometry assay.
Enrichment of BMAP-18 from spiked human whole blood,
plasma or serum was attempted using affinity-purified anti-BMAP
antibodies and capture of the antibody-peptide complexes by
magnetic Dynabeads, followed by detection of the eluted peptide
by MALDI-TOF mass spectrometry. The results are shown in
Figure 7. We easily detected intact (non-degraded) BMAP-18
(2342.57 m/z; Panel A) after 18 hours of incubation in human
blood or plasma, indicating that it is remarkably stable and
suggesting that it would remain intact for a reasonable time in the
blood of humans if it were used as a potential therapeutic. In
contrast, we were unable to detect intact BMAP-18 in human
serum (data not shown), perhaps because of the increased
proteolytic activity in serum after activation of the clotting cascade.
Discussion
Many of the parasites that cause disease remain problematic
since in the absence of effective vaccines, control measures rely
heavily on prophylactic or therapeutic drugs that have undesirable
characteristics. Many therapeutics are prohibitively expensive to
the people that need them and have unacceptable toxicity. In
addition, there is increasing drug resistance in the target
populations of parasites, for example in African trypanosomes
[2] and Leishmania [3]. There is thus a need for new anti-parasite
effectors that have more desirable features, such as a broad
spectrum of activity, low toxicity for the recipient and a low
propensity to induce microbial resistance. Host defense peptides
have many of these features thus were chosen for our initial work
on protozoan parasites [15] and for the work reported here.
HDP are a class of antimicrobial agents with promising
applications across the spectrum of human and animal disease
[4]. These peptides don’t simply target a single species of microbial
pathogen but work on two fronts. First, HDP can kill a broad
range of microbial pathogens directly by perturbation of their
plasma membranes or by permeating them and attacking an
internal target. Second, HDP can selectively modulate innate host
defenses [7–9]. Such an integrated mode of action is without
question an attractive alternative to the standard use of
antimicrobials, including the classic antibiotics. In fact, various
HDP have shown potential as therapeutics for sepsis [42,43] and
bacterial [44] infections. Although these applications in vivo and
other developments in vitro are encouraging, the practical use of
these peptides in vivo still presents problems that must be overcome.
Some HDP are inhibited by salt, even at physiological concen-
trations [45] and some peptides are toxic to mammalian cells [10].
In addition, some HDP (for example, the human cathelicidin LL-
37) are too large for routine production by standard peptide
synthesis techniques and some have proven difficult to express as
recombinant peptides in bacteria or yeast due in part to toxicity
issues. In the work presented here, we have addressed some of
these issues by testing BMAP-18, a truncated form [10] of the
bovine cathelicidin BMAP-27, in various assays in vitro, in order to
assess the utility of this truncated peptide for potential application
in vivo.
The highly trypanocidal BMAP-27 molecule [15] was first
shown by Skerlavaj et al to be cytotoxic for mammalian cells, a
problem partially solved by synthesizing a truncated form, BMAP-
27 [1–18] (now called BMAP-18) that had the hydrophobic C-
terminal segment removed [10]. In the work reported here, we
compared BMAP-27 and BMAP-18 for their ability to kill a
variety of species of protozoan parasites, including African
trypanosomes, the infamous pathogens of humans and livestock
in Africa, a trypanosome (T. danilewskyi) that is an economically
important fish pathogen [24] and Leishmania donovani, an important
human pathogen. Both forms of the peptide effectively inhibited
all of these species in vitro, showing a broad range of specificity.
Importantly, when compared to BMAP-27, BMAP-18 showed
only a slight reduction in its ability to kill these parasites
(approximately 2 fold more peptide required for 50% killing)
and showed reduced toxicity (2–6 fold) on six different mammalian
cell lines and three different insect cell lines. Thus, consistent with
the findings of Skerlavaj et al [10], removal of the C-terminal 9
amino acids from BMAP-27 resulted in a molecule with greatly
reduced cytotoxicity for non-microbial cells.
BMAP-18 killed both major life cycle stages of African
trypanosomes (BSF and PCF) but was much less effective at
killing the bacterial symbiont, Sodalis glossinidius. These results
support the idea that BMAP-18 could potentially be used to treat
trypanosome-infected animals or to inhibit the parasites in their
tsetse vector. The latter could be attempted by interfering with
Figure 6. Inhibition of LPS-induced TNF-a secretion from human PBMC by BMAP-27 and BMAP-18. PBMC were incubated with 5 mg/mL
of BMAP-27 or BMAP-18 for 30 minutes before treating with highly purified Pseudomonas aeruginosa lipopolysaccharide (10 ng/mL). After 4 hours,
TNF-a was measured in the supernatants by ELISA. Gray bar: PBMC incubated with LPS alone. Black bars: PBMC incubated with BMAP-27 or with
BMAP-18. The asterisks indicate the responses after treatment with LPS (p,0.01 comparing LPS alone to LPS+peptide). Three complete biological
replicates were performed and the standard errors are shown.
doi:10.1371/journal.pntd.0000373.g006
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Figure 7. Mass spectrometric detection of intact BMAP-18 peptide after immunoenrichment from human plasma by anti-BMAP
antibodies. MALDI-TOF mass spectrometry was used to determine the peptide mass spectra of eluates from Dynabeads used to capture antibody-
BMAP-18 complexes from human plasma. Panel A shows the spectrum obtained from 50 mL of human plasma spiked with 1.0 mg of BMAP-18
peptide after capture of BMAP-18 with affinity-purified anti-BMAP-18 antibody. Panel B shows the spectrum obtained when no peptide was spiked
into the plasma. This negative control reveals that no off-target binding occurred. In Panel A the average mass is the peak indicated by the arrow at
2342.57 m/z. A smaller peak at 1886.64 m/z was also seen and is likely a degradation product of BMAP-18. Both Panel A and Panel B show
accumulated spectra. This experiment was repeated twice and similar results were observed.
doi:10.1371/journal.pntd.0000373.g007
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trypanosome development in tsetse, perhaps by expression of the
trypanocidal peptide in Sodalis glossinidius using paratransgenesis
strategies [46]. BMAP-18 was also toxic to the fish pathogen
Trypanosoma danilewskyi and to free-living Leishmania donovani
promastigotes. We did not test whether or not BMAP-18 can
penetrate Leishmania infected macrophages to kill the intracellular
amastigote forms so its therapeutic potential for the Leishmaniases
remains unknown.
BMAP-18 was shown to induce an apoptosis-like cell death in
African trypanosomes and at higher concentrations caused
membrane damage and subsequent death of the parasites by
necrosis. We also tested whether or not BMAP-18 has immuno-
modulatory potential. Both the parent molecule, BMAP-27, and
its truncated form, BMAP-18, failed to directly stimulate TNF-a
secretion from HPBL but also strongly inhibited TNF-a release
from LPS-stimulated HPBL. This may have practical implications
for use of BMAP-18 as a therapeutic since TNF-a is a potent
inflammatory cytokine that negatively affects trypanosome-infect-
ed animals. It will be of particular interest to test the bovine-
derived BMAP-18 molecule for treatment of trypanosomiasis in
cattle since there is evidence that a cathelicidin can be effective in
treatment of disease in the species of animal from which the HDP
was derived [47].
Since relatively large amounts of BMAP-18 will be required for
testing in animals, it is of interest that stable integration of the
BMAP-18 coding sequence and expression of BMAP-18 RNA has
been achieved in transgenic potato plants (Teresa Francescutti,
Biochemistry Dept, University of Victoria, personal communica-
tion). So far however, detection of the peptide itself has not been
accomplished.
In anticipation of in vivo testing, we developed antibodies to
BMAP-18 for measurement of the peptide in the blood of treated
animals or in the midgut or hemolymph of tsetse. Even after
18 hours of incubation in freshly prepared, undiluted whole blood
or plasma, intact (non-degraded) BMAP-18 was detected after
antibody enrichment followed by MALDI-TOF mass spectrom-
etry. This is encouraging because quantitative detection of BMAP-
18 by standard immunological techniques, such as sandwich
ELISA, will be problematic, since as a very small peptide, BMAP-
18 likely does not contain two distinct epitopes, the minimal
requirement for such assays. The fact that we could detect low
levels of BMAP-18 by mass spectrometry, after enrichment of the
peptide from human blood or plasma using a single antibody,
bodes well for development of assays such as iMALDI [48] or
SISCAPA [49] for quantitation of BMAP-18 and other HDP in
complex biological fluids.
Conclusion
Host defense peptides show great promise as therapeutics for a
variety of infectious diseases. Here we have shown that BMAP-18
exhibits potent killing activity in vitro against a broad range of
socioeconomically important parasites that infect humans, cattle
and fish. However, for therapeutic applications in vivo, there are
ongoing concerns about HDP toxicity, serum sensitivity and
stability of the effector peptides in the blood of treated animals. In
addition, there is evidence that resistance to direct anti-microbial
killing by cationic peptides may arise, at least in some bacteria (50),
thus any immunomodulatory effects of HDP are a welcome
adjunct to direct killing. We have, in part, addressed these
concerns for BMAP-18. First, BMAP-18 exhibited reduced
toxicity on mammalian and insect cell lines. Second, BMAP-18
killing activity against several species of free-living parasites was
potent in the presence of 10% fetal bovine serum in the culture
medium used. Third, BMAP-18 could be detected by mass
spectrometry in an unaltered form after enrichment from both
whole blood and plasma using anti-peptide antibodies. Fourth, it
was shown that BMAP-18 strongly inhibited LPS-induced release
of TNF-a from leukocytes. Since TNF-alpha is one of the causes of
cachexia (wasting) associated with African sleeping sickness (51)
and is involved in immunosuppression in trypanosome infected
animals (52), the data suggest that BMAP-18 is an excellent
candidate for testing in vivo as a therapeutic that would directly kill
trypanosomes while helping to maintain the overall health of the
infected host.
Acknowledgments
We thank Sam Black for T. b. brucei 427.01 bloodstream forms and for
advice regarding their culture in vitro, Sam Turco for Leishmania
promastigotes, Debbie Plouffe and Mike Belosevic for T. danilewskyi
cultures, Beatrixe Whittome for her expert help with growth and
harvesting of the insect cell lines, and Melissa Elliot for her helpful advice
and for performing the immunomodulation assays.
Author Contributions
Conceived and designed the experiments: LRH TWP. Performed the
experiments: LRH JMT AMJ BAE MR CNW BG. Analyzed the data:
LRH JMT AMJ BAE MR TWP. Contributed reagents/materials/analysis
tools: BG REWH TWP. Wrote the paper: LRH JMT REWH TWP.
References
1. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ,
Krishna S (2003) The trypanosomiases. Lancet 362: 1469–1480.
2. Delespaux V, de Koning HP (2007) Drugs and drug resistance in African
trypanosomiasis. Drug Resist Update 10: 30–50.
3. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin
Microbiol Rev 19: 111–126.
4. Mookherjee N, Hancock REW (2007) Cationic host defense peptides: innate
immune regulatory peptides as a novel approach for treating infections. Cell Mol
Life Sci 64: 922–933.
5. Wang Z, Wang G (2004) APD: the Antimicrobial Peptide Database. Nucleic
Acids Res 32: D590–D592.
6. The Antimicrobial Peptide Database [http://aps.unmc.edu/AP/main.html].
7. Risso A, Zanetti M, Gennaro R (1998) Cytotoxicity and apoptosis mediated by
two peptides of innate immunity. Cell Immunol 189: 107–115.
8. Risso A (2000) Leukocyte antimicrobial peptides: multifunctional effector
molecules of innate immunity. J Leukocyte Biol 68: 785–792.
9. Zanetti M (2004) Cathelicidins, multifunctional peptides of the innate immunity.
J Leukocyte Biol 75: 39–48.
10. Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M (1996)
Biological characterization of two novel cathelicidin-derived peptides and
identification of structural requirements for their antimicrobial and cell lytic
activities. J Biol Chem 271: 28375–28381.
11. Benincasa M, Scocchi M, Pacor S, Tossi A, Nobili D, Basaglia G, Busetti M,
Gennaro R (2006) Fungicidal activity of five cathelicidin peptides against
clinically isolated yeasts. J Antimicrob Chemother 58: 950–959.
12. Donati M, Di Francesco A, Gennaro R, Benincasa M, Magnino S, Pignanelli S,
Shurdhi A, Moroni A, Mazzoni C, Merialdi G, Baldelli R, Cevenini R (2007)
Sensitivity of Chlamydia suis to cathelicidin peptides. Vet Microbiol 123: 269–273.
13. Wang G, Watson KM, Buckheit RW Jr (2008) Anti-HIV-1 Activity of
Antimicrobial Peptides Derived from Human and Bovine Cathelicidins.
Antimicrob Agents Chemother 52: 3438–3440.
14. McGwire BS, Olson CL, Tack BF, Engman DM (2003) Killing of African
trypanosomes by antimicrobial peptides. J Infect Dis 188: 146–152.
15. Haines LR, Hancock REW, Pearson TW (2003) Cationic antimicrobial peptide
killing of African trypanosomes and Sodalis glossinidius, a bacterial symbiont of the
insect vector of sleeping sickness. Vector Borne Zoonotic Dis 3: 175–186.
16. Cross GA, Manning JC (1973) Cultivation of Trypanosoma brucei sspp. in semi-
defined and defined media. Parasitol 67: 315–331.
17. Baltz T, Baltz D, Giroud C, Crockett J (1985) Cultivation in a semi-defined
medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T.
rhodesiense and T. gambiense. EMBO J 4: 1273–1277.
18. Gray AR (1972) Variable agglutinogenic antigens of Trypanosoma gambiense and
their distribution among isolates of the trypanosome collected in different places
in Nigeria. Trans R Soc Trop Med Hyg 66: 263–284.
Killing of Parasites by BMAP-18
www.plosntds.org 12 February 2009 | Volume 3 | Issue 2 | e373
19. Anderson NL, Parish NM, Richardson JP, Pearson TW (1985) Comparison of
African trypanosomes of different antigenic phenotypes, subspecies and life cycle
stages by two-dimensional gel electrophoresis. Mol Biochem Parasitol 16:
299–314.
20. Fish WR, Muriuki CW, Muthiani AM, Grab DJ, Lonsdale-Eccles JD (1989)
Disulfide bond involvement in the maintenance of the cryptic nature of the
cross-reacting determinant of metacyclic forms of Trypanosoma congolense.
Biochemistry 28: 5415–5421.
21. Brun R, Schonenberger M (1979) Cultivation and in vitro cloning of procyclic
culture forms of Trypanosoma brucei in a semi-defined medium. Acta Tropica 36:
289–292.
22. Agbo EC, Clausen PH, Bu¨scher P, Majiwa PA, Claassen E, te Pas MF (2003)
Population genetic structure and cladistic analysis of Trypanosoma brucei isolates.
Infect Genet Evol 3: 165–174.
23. Stebeck CE, Beecroft RP, Singh BN, Jardim A, Olafson RW, Tuckey C,
Prenevost KD, Pearson TW (1995) Kinetoplastid membrane protein-11 (KMP-
11) is differentially expressed during the life cycle of African trypanosomes and is
found in a wide variety of kinetoplastid parasites. Mol Biochem Parasitol 71:
1–13.
24. Bienek DR, Belosevic M (1997) Comparative assessment of growth of
Trypanosoma danilewskyi (Laveran and Mesnil) in medium containing fish or
mammalian serum. J Fish Dis 20: 217–221.
25. Turco SJ, Descoteaux A (1992) The lipophosphoglycan of Leishmania parasites.
Annu Rev Microbiol 46: 65–94.
26. Gorer PA (1950) Studies in antibody response of mice to tumour inoculation.
Br J Cancer 4: 372–379.
27. Todaro GJ, Green H (1963) Quantitative studies of the growth of mouse embryo
cells in culture and their development into established lines. J Cell Biol 17:
299–313.
28. Helmke RJ, Boyd RL, German VF, Mangos JA (1987) From growth factor
dependence to growth factor responsiveness: the genesis of an alveolar
macrophage cell line. In Vitro Cell Dev Biol 23: 567–574.
29. Jones HW Jr, McKusick VA, Harper PS, Wuu KD (1971) George Otto Gey.
(1899–1970). The HeLa cell and a reappraisal of its origin. Obstet Gynecol 38:
945–949.
30. Palli SR, Retnakaran A, Sohi SS (1997) Analysis of ecdysteroid action in
Choristoneura fumiferana CF-70 cells. In: Maramorosch, Mitsuhashi J, eds.
Inveretebrate cell culture: Novel Directions and Biotechnology Applications.
Enfield, NH: Science Publishers, Inc. pp 85–91.
31. Smith GE, Ju G, Ericson BL, Moschera J, Lahm HW, Chizzonite R,
Summers MD (1985) Modification and secretion of human interleukin 2
produced in insect cells by a baculovirus expression vector. Proc Natl Acad
Sci U S A 82: 8404–8408.
32. Sohi SS, Ennis TJ (1981) Chromosomal characterization of cell lines of Neodiprion
lecontei (Hymenoptera; diprionidae). Proc Entomol Society of Ontario 112:
45–48.
33. Grace TDC (1962) Establishment of four strains of cells from insect tissues
grown in vitro. Nature 195: 788–789.
34. O’Neill SL, Gooding RH, Aksoy S (1993) Phylogenetically distant symbiont
microorganisms reside in Glossina midgut and ovary tissues. Med Vet Entomol 7:
377–383.
35. Welburn SC, Maudlin I, Ellis DS (1987) In vitro cultivation of rickettsia-like-
organisms from Glossina spp. Ann Trop Med Parasitol 81: 331–335.
36. Haines LR, Haddow JD, Aksoy S, Gooding RH, Pearson TW (2002) The major
protein in the midgut of teneral Glossina morsitans morsitans is a molecular
chaperone from the endosymbiotic bacterium Wigglesworthia glossinidia. Insect
Biochem Mol Biol 32: 1429–1438.
37. Onyango JD, Burri C, Brun R (2000) An automated biological assay to
determine levels of the trypanocidal drug melarsoprol in biological fluids. Acta
Trop 74: 95–100.
38. Ahmed SA, Gogal RM Jr, Walsh JE (1994) A new rapid and simple non-
radioactive assay to monitor and determine the proliferation of lymphocytes: an
alternative to [3H]thymidine incorporation assay. J Immunol Meth 170:
211–224.
39. Johnson LV, Walsh ML, Chen LB (1980) Localization of mitochondria in living
cells with rhodamine 123. Proc Natl Acad Sci U S A 77: 990–994.
40. Darveau RP, Hancock REW (1983) Procedure for isolation of bacterial
lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and
Salmonella typhimurium strains. J Bacteriol 155: 831–838.
41. Tolson DL, Turco SJ, Beecroft RP, Pearson TW (1989) The immunochemical
structure and surface arrangement of Leishmania donovani lipophosphoglycan
determined using monoclonal antibodies. Mol Biochem Parasitol 35: 109–118.
42. Cirioni O, Ghiselli R, Tomasinsig L, Orlando F, Silvestri C, Skerlavaj B, Riva A,
Rocchi M, Saba V, Zanetti M, Scalise G, Giacometti A (2008) Efficacy of LL-37
and granulocyte colony-stimulating factor in a neutropenic murine sepsis due to
Pseudomonas aeruginosa. Shock 30: 443–448.
43. Mookherjee N, Rehaume LM, Hancock RE (2007) Cathelicidins and functional
analogues as antisepsis molecules. Expert Opin Ther Targets 11: 993–1004.
44. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A,
Wang A, Lee K, Doria S, Hamill P, Yu JJ, Li Y, Donini O, Guarna MM,
Finlay BB, North JR, Hancock REW (2007) An anti-infective peptide that
selectively modulates the innate immune response. Nat Biotechnol 25: 465–472.
45. Wu M, Maier E, Benz R, Hancock REW (1999) Mechanism of interaction of
different classes of cationic antimicrobial peptides with planar bilayers and with
the cytoplasmic membrane of Escherichia coli. Biochemistry 38: 7235–7242.
46. Aksoy S, Weiss B, Attardo G (2008) Paratransgenesis applied for control of tsetse
transmitted sleeping sickness. Adv Exp Med Biol 627: 35–48.
47. Brogden KA, Kalfa VC, Ackermann MR, Palmquist DE, McCray PB Jr,
Tack BF (2001) The ovine cathelicidin SMAP29 kills ovine respiratory
pathogens in vitro and in an ovine model of pulmonary infection. Antimicrob
Agents Chemother 45: 331–334.
48. Jiang J, Parker CE, Fuller JR, Kawula TH, Borchers CH (2007) An
immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of
Francisella tularensis. Anal Chim Acta 605: 70–79.
49. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW,
Pearson TW (2004) Mass spectrometric quantitation of peptides and proteins
using Stable Isotope Standards and Capture by Anti-Peptide Antibodies
(SISCAPA). J Proteome Res 3: 235–244.
50. Kraus D, Herbert S, Kristian SA, Khosravi A, Nizet V, Gotz F, Peschel A (2008)
The GraRS regulatory system controls Stapylococcus aureus susceptibility to
antimicrobial host defense. BMC Microbiol 8: 85–90.
51. Okomo-Assoumou MC, Daulouede S, Lemesre J-L, N’Zila-Mouanda A,
Vincendeau P (1995) Correlation of high serum levels of tumour necrosis
factor-a with disease severity in human African trypanosomiasis. Am J Trop
Med Hyg 53: 539–543.
52. Darji A, Beschin A, Sileghem M, Heremans H, Brys L, De Baetselier P (1996) In
vitro simulation of immunosuppression caused by Trypanosoma brucei: active
involvement of gamma interferon and tumor necrosis factor in the pathway of
suppression. Infect Immun 64: 1937–1943.
Killing of Parasites by BMAP-18
www.plosntds.org 13 February 2009 | Volume 3 | Issue 2 | e373
